Doc,
I'm of the belief that future growth is a greater priority than profit. Take a look at SGEN, it's had very few profitable quarters but has routinely built both sales and the size of it's pipeline. It's share price has grown dramatically in spite of no profits and now it's being bought out.
Certainly, if the company stopped all the clinical trials and product development they would become highly profitable instantaneously, but companies don't do that. As long as new products in development continue to show potential investors are happy with the growth and willing to purchase additional stock at ever increasing prices.
I'm frankly uncertain how many additional products NWBO may develop once both DCVax's are approved, but if we're right about the vaccines benefitting many with all sorts of solid cancers we'll have tremendous sales growth and profits whether we develop other products or not. Right now the key is getting that initial approval, then many others to follow and tremendous growth in manufacturing capacity. The profits will certainly come, but not for awhile.
Gary
Market Data 
Markets 
AI
